Camlipixant(Camlipixant) - 药物靶点：P2X3 receptor_在研适应症：不明原因的慢性咳嗽，难治性慢性咳嗽，咳嗽_专利_临床

概要

基本信息

药物类型

小分子化药

别名

AZ-13410937、AZ13410937、BLU 5937

+ [3]

靶点

P2X3 receptor

作用方式

拮抗剂

作用机制

P2X3 receptor拮抗剂(嘌呤P2X3受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

BELLUS Health, Inc.BELLUS Health Cough, Inc.

Neomed Institute

非在研机构-

权益机构

BELLUS Health, Inc.

GSK Plc

Neomed Institute

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H24F2N4O4

InChIKeySEHLMRJSQFAPCJ-HNNXBMFYSA-N

CAS号1621164-74-6

关联

15

项与 Camlipixant 相关的临床试验

NCT06497517

/ Completed临床1期

A Phase 1, Single Center, Single Dose, Open-Label, Randomized, 2-Way Crossover Study to Investigate the Food Effect on the Pharmacokinetics of Camlipixant in Healthy Male and Female Participants

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

开始日期2024-07-09

申办/合作机构

BELLUS Health, Inc.

CTR20240965

/ Recruiting临床3期

一项在难治性或不明原因慢性咳嗽成人受试者中进行BLU-5937开放性扩展治疗的III期、24周、随机、疗效和安全性研究

主要目的：评估BLU-5937与安慰剂相比在基线24小时咳嗽频率≥8次咳嗽/小时的RCC（包括不明原因的慢性咳嗽）成人患者中对第24周时24小时咳嗽频率的影响以及确定截至第24周时BLU-5937与安慰剂相比在RCC（包括不明原因的慢性咳嗽）成人患者中的安全性次要目的：评价BLU-5937对咳嗽频率和PRO等其他指标的影响探索性目的：评价BLU-5937对咳嗽频率和PRO等其他指标的影响

开始日期2024-06-21

申办/合作机构

Patheon, Inc.

[+3]

NCT05570539

/ Completed临床1期

A Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects

This is a Phase 1, Single-Centre, Open-Label, Two-Part, Sequential Cross-Over Study Designed to Assess the Pharmacokinetic Profile of BLU-5937 Following Administration of Extended Release Formulation Prototypes and an Immediate Release Reference Formulation in Healthy Male and Female Subjects

开始日期2024-03-14

申办/合作机构

BELLUS Health, Inc.

100 项与 Camlipixant 相关的临床结果

登录后查看更多信息

100 项与 Camlipixant 相关的转化医学

登录后查看更多信息

100 项与 Camlipixant 相关的专利（医药）

登录后查看更多信息

10

项与 Camlipixant 相关的文献（医药）

2025-01-01·JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist

Article

作者: Thach, Trung ; Subramanian, Ramaswamy ; Snyder, Jonathan ; Heisler, Iring ; Stauffer, Seth ; Dhanabalan, KanagaVijayan ; Alvarado, Sarah ; Nandekar, Prajwal Prabhakarrao

ATP-activated P2X3 receptors play a pivotal role in chronic cough, affecting more than 10% of the population. Despite the challenges posed by the highly conserved structure of P2X receptors, efforts to develop selective drugs targeting P2X3 have led to the development of camlipixant, a potent, selective P2X3 antagonist. However, the mechanisms of receptor desensitization, ion permeation, and structural basis of camlipixant binding to P2X3 remain unclear. Here, we report a cryo-EM structure of camlipixant-bound P2X3, revealing a previously undiscovered selective drug-binding site in the receptor. Our findings also demonstrate that conformational changes in the upper body domain, including the turret and camlipixant-binding pocket, play a critical role: turret opening facilitates P2X3 channel closure to a radius of 0.7 Å, hindering cation transfer, whereas turret closure leads to channel opening. Structural and functional studies combined with molecular dynamics simulations provide a comprehensive understanding of camlipixant's selective inhibition of P2X3, offering a foundation for future drug development targeting this receptor.

2024-11-01·CHEST

Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough

Review

作者: Horita, Nobuyuki ; Obase, Yasushi ; Hara, Johsuke ; Niimi, Akio ; Hara, Yu ; Mukae, Hiroshi ; Sasamoto, Mao ; Kanemitsu, Yoshihiro ; Yamamoto, Shota ; Kaneko, Takeshi

BACKGROUND:

Refractory or unexplained chronic cough disrupts quality of life and burdens health care systems around the world. The P2X3 receptor antagonist gefapixant is approved in many countries for its antitussive effects, but taste disturbances are a common adverse effect. Four newer, more selective P2X3 receptor antagonists have been developed to address this problem.

RESEARCH QUESTION:

How does the benefit-risk profile vary across the five available P2X3 receptor antagonists?

STUDY DESIGN AND METHODS:

A systematic review and network meta-analysis was conducted to evaluate the efficacy of P2X3 receptor antagonists, including gefapixant, sivopixant, eliapixant, camlipixant, and filapixant. Primary outcomes were a reduction rate in 24-hour cough frequency and incidence of taste disturbance. Dose-response curves and median effective dose (ED₅₀) were calculated. Effect size at ED₅₀ was ranked according to the surface under the cumulative ranking curve. The confidence was evaluated by Confidence In Network Meta-Analysis.

RESULTS:

Sixteen randomized controlled trials involving 4,904 participants were analyzed. The gefapixant regimen demonstrated an ED₅₀ of 90.7 mg/d for cough frequency reduction. Gefapixant showed the highest antitussive effectiveness at ED₅₀ (reduction rate in 24-hour cough frequency: median, 28.1%; 95% credible interval [CrI], 21.0%-35.6%; ranked 1 of 5; moderate certainty) but the highest prevalence of taste disturbance (absolute risk difference per 100 patients: median, 38; 95% CrI, 27-51; ranked 5 of 5; high certainty) and the highest prevalence of discontinuation. Camlipixant had a well-balanced profile (reduction rate in 24-hour cough frequency: median, 14.7%; 95% CrI, 5.4%-26.0%; ranked 3 of 5; low certainty; and taste disturbance; absolute risk difference per 100 patients; median, 2; 95% CrI, 1-6; ranked 2 of 5; low certainty). Placebo had a mean of 33.1% reduction in 24-hour cough frequency.

INTERPRETATION:

When used at safe doses, gefapixant had a favorable risk-benefit profile compared with the other four agents. Camlipixant showed initial promise, which may be further investigated by phase III trials currently underway.

CLINICAL TRIAL REGISTRATION:

University Hospital Medical Information Network Center (UMIN-CTR); No. UMIN000050622; URL: https://center6.umin.ac.jp.

2024-08-22·JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Triazolopyrimidine Derivatives as Selective P2X3 Receptor Antagonists Binding to an Unprecedented Allosteric Site as Evidenced by Cryo-Electron Microscopy

Article

作者: Jin, Mi Sun ; Nagel, Jessica ; Müller, Christa E. ; Kim, Yeo-Ok ; Kim, Jihyun ; Song, Dahin Irene ; Yoon, Myung-Ha ; Kim, Ga-Ram ; Kim, Yong-Chul ; Han, Xuehao ; Kim, Subin

The P2X3 receptor (P2X3R), an ATP-gated cation channel predominantly expressed in C- and Aδ-primary afferent neurons, has been proposed as a drug target for neurological inflammatory diseases, e.g., neuropathic pain, and chronic cough. Aiming to develop novel, selective P2X3R antagonists, tetrazolopyrimidine-based hit compound 9 was optimized through structure-activity relationship studies by modifying the tetrazole core as well as side chain substituents. The optimized antagonist 26a, featuring a cyclopropane-substituted triazolopyrimidine core, displayed potent P2X3R-antagonistic activity (IC₅₀ = 54.9 nM), 20-fold selectivity versus the heteromeric P2X2/3R, and high selectivity versus other P2XR subtypes. Noncompetitive P2X3R blockade was experimentally confirmed by calcium influx assays. Cryo-electron microscopy revealed that 26a stabilizes the P2X3R in its desensitized state, acting as a molecular barrier to prevent ions from accessing the central pore. In vivo studies in a rat neuropathic pain model (spinal nerve ligation) showed dose-dependent antiallodynic effects of 26a, thus presenting a novel, promising lead structure.

103

项与 Camlipixant 相关的新闻（医药）

2025-03-10

·Endpoints

Trevi’s mid-stage chronic cough data meet ‘home run’ scenario, stock soars

Trevi Therapeutics’ chronic cough drug reduced patients’ 24-hour cough frequency by 57% compared to placebo in a Phase 2a trial, exceeding investors’ expectations. The company’s stock $TRVI soared 40% at market open as a result. Leerink analysts said the data hit a “home run scenario,” noting that the candidate, named Haduvio, showed similar efficacy in patients with both moderate and severe cough at baseline. In the RIVER study, patients with severe cough at baseline saw a 66% reduction in 24-hour cough frequency after taking the treatment, while those in the moderate cough group had a 68% reduction (both with a p-value of less than 0.0001). Haduvio is an oral extended-release version of an old pain medicine called nalbuphine. According to Trevi, the drug works on opioid receptors that play a role in controlling cough hypersensitivity. Nalbuphine is not currently considered a controlled substance , which refers to a drug or substance regulated by the government because of its potential for abuse or addiction. A Trevi spokesperson told Endpoints News that the company doesn’t expect Haduvio to be scheduled as a controlled substance. In its news release, the company said that there were no treatment-emergent serious adverse events. The company plans on discussing its next steps with the FDA and expects to initiate the next study with the agency’s input. “The competitive landscape in the last couple of years has thinned out due to multiple failures,” Trevi’s CEO Jennifer Good said on a Monday morning call with investors. “With the strength of the RIVER data and the sparse competitive landscape, we believe Haduvio has the potential to be best-in-class in patients with RCC.” RCC refers to refractory chronic cough, or a persistent cough lasting more than eight weeks that isn’t resolved by standard treatments. There are currently no approved treatments for RCC. Trevi’s main competitor in RCC is GSK’s Phase 3 candidate camlipixant, which was a focal point of its $2 billion Bellus acquisition in 2023. The company is set to read out late-stage results in the second half of this year. While it is nearly impossible to compare data across trials, recently published Phase 2b camlipixant results showed a placebo-adjusted reduction in 24-hour cough rate of 34% in patients who experienced 25 or more coughs per hour at baseline. Trevi classified severe cough as patients who experience 20 or more coughs per hour. Trevi made clear that idiopathic pulmonary fibrosis, a chronic lung disease, is still its priority for Haduvio. The company expects to have Phase 2b results in IPF patients with chronic cough in the second quarter.

临床2期临床结果临床3期并购

2025-03-10

·Firstwordpharma

Trevi soars on hopes for refractory chronic cough treatment

With no FDA-approved treatments for refractory chronic cough (RCC), patients have long faced limited options – but Trevi Therapeutics is hoping to change that. On Monday, the company announced that its investigational oral therapy Haduvio (nalbuphine extended-release) met its primary endpoint in the Phase IIa RIVER trial, showing a statistically significant 57% placebo-adjusted reduction in 24-hour cough frequency.The crossover study, which enrolled 66 patients with RCC, demonstrated that Haduvio reduced cough frequency by 67% from baseline, compared to 10% with placebo. The therapy also showed similar efficacy in both moderate (10-19 coughs/hour) and severe (20+ coughs/hour) patient subgroups, with reductions of 68% and 66%, respectively.Trevi plans to discuss next steps with the FDA while continuing its parallel Phase IIb CORAL trial in chronic cough associated with idiopathic pulmonary fibrosis (IPF), which recently completed enrollment. Topline results there are due this half."The RIVER trial demonstrated that Haduvio was highly effective, and worked quickly at the lowest dose tested across a broad range of cough counts," said CEO Jennifer Good. "These results, coupled with our existing IPF chronic cough results, are further evidence of the effectiveness of Haduvio's central and peripheral KAMA mechanism in treating these difficult neurological cough conditions." Company shares were up over 41% on the news Monday.While Trevi's success may be capturing investor attention, other players have struggled to gain traction in the space. In 2023, Merck & Co. received a second complete response letter from the FDA for its oral P2X3 receptor antagonist gefapixant, despite the drug being approved in Europe and Japan. The US regulator had concluded that Merck's application "did not meet substantial evidence of effectiveness" for treating refractory or unexplained chronic cough.Meanwhile, GSK is hoping camlipixant, another P2X3 antagonist, can help turn the company's fortunes around (see – Vital Signs: Pharma's worst performers of 2024, and how they can turn the tide in 2025). Phase III results for the drug, which GSK acquired through its $2-billion deal for Bellus Health, are expected at the end of this year.In Phase IIb SOOTHE trial results published earlier this month in the American Journal of Respiratory and Critical Care Medicine, camlipixant demonstrated a 34% placebo-adjusted reduction in 24-hour cough frequency.Before the RIVER readout, Oppenheimer analysts said they "lean optimistic that Haduvio's performance in RIVER will open the door to a sizable second opportunity in RCC patients inadequately addressed by other therapies." Specifically, they highlighted that efficacy in the severe cough segment would "best inform its prospects for those in whom alternatives, including GSK's Phase III-stage camlipixant, are insufficient."

临床2期临床结果临床3期

2025-02-13

·新药前沿

恒瑞退出P2X3拮抗剂竞争？

根据恒瑞官网今年1月更新的研发管线，该公司似乎已经放弃了难治性慢性咳嗽（RCC）或不明原因慢性咳嗽（UCC）P2X3拮抗剂项目HRS-2261。 2023年2月，恒瑞在CDE药物临床试验登记与信息公示平台登记了一“HRS-2261治疗难治性慢性咳嗽的有效性和安全性的多中心、随机、双盲、平行、安慰剂对照II期临床研究”（CTR20230367），截至目前试验状态仍旧为“进行中-招募中”。然而，在此后的短短不足2年里，P2X3拮抗剂领域经历了几起大事件： 2023年4月，葛兰素史克以20亿美元收购BELLUS Health获得camlipixant，将会加速后者该项目的开发速度，也意味着未来该市场又一强劲竞争对手的出现。 2023年12月，默沙东的gefapixant第二次遭FDA拒绝批准，在美国的上市前景变得异常渺茫。国内P2X3拮抗剂follow者竞争同样激烈，朗来科技的QR-052107B已完成II期临床研究，而豪森的HS-10383也已进入Ⅱ期临床试验中。很显然，继续开发P2X3拮抗剂或许已经不再符合恒瑞的研发战略了。延伸阅读：恒瑞10个月把4条呼吸新药管线推进Ⅰ期，加速开拓新治疗领域本文由「新药前沿」微信公众号根据公开资料整理编辑，欢迎个人转发至朋友圈。媒体或机构转载授权请在「新药前沿」微信公众号留言公众号名称，审核通过后开通白名单获取转载授权，转载请标识来源。免责声明：本文仅作信息交流之目的，非投资建议或者治疗方案推荐，「新药前沿」微信公众号不对任何主体因使用本文内容而导致的任何损失承担责任。限于作者水平和专业知识所限，如有谬误，欢迎指正！

临床2期并购引进/卖出临床终止

100 项与 Camlipixant 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不明原因的慢性咳嗽	临床3期	中国	BELLUS Health Cough, Inc.	2024-06-21
不明原因的慢性咳嗽	临床3期	日本	BELLUS Health Cough, Inc.	2024-06-21
不明原因的慢性咳嗽	临床3期	澳大利亚	BELLUS Health Cough, Inc.	2024-06-21
不明原因的慢性咳嗽	临床3期	捷克	BELLUS Health Cough, Inc.	2024-06-21
不明原因的慢性咳嗽	临床3期	印度	BELLUS Health Cough, Inc.	2024-06-21
难治性慢性咳嗽	临床3期	美国	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	阿根廷	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	比利时	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	加拿大	BELLUS Health, Inc.	2022-10-25
难治性慢性咳嗽	临床3期	哥伦比亚	BELLUS Health, Inc.	2022-10-25

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05959447 (CTgov)	临床1期	咳嗽	45	Gemfibrozil+Camlipixant (Part 1: Camlipixant 50 mg + Gemfibrozil 600 mg)	壓簾糧憲廠餘膚襯構鬱(襯鬱糧網憲鑰齋糧夢餘) = 鏇網獵壓醖襯鹹積鹽壓襯鹽餘衊鏇簾襯齋衊遞 (願齋壓範鬱壓廠壓齋鹽, 28.69) 更多	-	2025-03-26
				Dabigatran etexilate+Camlipixant (Part 2: Dabigatran Etexilate 150 mg + Camlipixant 50 mg)	齋壓憲窪齋齋積鑰製夢(鑰淵積鬱築範網鹽艱壓) = 窪齋壓糧衊繭鬱願襯廠窪齋衊獵齋製簾淵餘網 (衊壓糧鹹憲夢蓋鹽蓋鑰, 52.12) 更多
NCT04678206 (SOOTHE, Pubmed \| Am J Respir Crit Care Med)	临床2期	难治性慢性咳嗽	310	Camlipixant 50 mg	製衊鏇繭廠築膚鏇觸廠(鹽選蓋構醖築艱窪積積) = 鏇憲窪製簾衊選築積夢範齋蓋窪醖遞襯壓壓艱 (襯膚選憲衊鹹積範膚壓, -50.5 ~ -13.3)	积极	2025-03-05
				Camlipixant 200 mg	製衊鏇繭廠築膚鏇觸廠(鹽選蓋構醖築艱窪積積) = 醖廠鏇網窪構鏇夢積遞範齋蓋窪醖遞襯壓壓艱 (襯膚選憲衊鹹積範膚壓, -50.7 ~ -12.2)
NCT05899829 (CTgov)	临床1期	咳嗽	42	Rifampin+Camlipixant (Part 1: Camlipixant 50 mg + Rifampin 600 mg)	醖簾衊願鑰積鏇襯範觸(鹽窪築遞壓獵範積鹹齋) = 鬱夢餘窪觸網構選鹹簾鹽顧膚顧獵鏇醖廠鑰鏇 (範夢鏇鏇齋簾願鬱繭壓, 39.27) 更多	-	2024-12-04
				Rabeprazole+Camlipixant (Part 2: Camlipixant 50 mg + Rabeprazole 20 mg)	簾顧窪構齋顧壓鏇顧壓(艱醖獵醖積淵選襯齋觸) = 膚蓋艱簾糧艱襯淵窪繭窪壓夢鏇窪簾廠選蓋鏇 (選網網願憲鏇獵簾網壓, 29.55) 更多
NCT04678206 (SOOTHE, ERS2022)	临床2期	难治性慢性咳嗽 P2X3	-	BLU-5937 12.5 mg BID	鹹製窪衊淵網網淵膚積(構齋壓顧糧製鬱構衊觸) = Treatment-emergent TDAEs were reported by 4.8, 6.5, 4.8 and 0% of participants in the 12.5, 50, 200 mg BID and placebo groups, respectively. Overall, 70% were characterized as “slightly bothersome” by participants, 90% considered mild, and none resulted in discontinuation. 鏇簾製鏇鹽鏇淵艱艱淵 (窪壓獵糧餘遞醖構壓窪 )	积极	2022-09-04
				BLU-5937 50 mg BID
NCT04678206 (SOOTHE, ERS2022)	临床2期	难治性慢性咳嗽	-	BLU-5937 12.5 mg BID	膚衊鑰淵齋範艱積廠繭(窪艱獵鬱觸糧鹹簾餘蓋) = 簾膚網鏇鏇獵顧齋鬱網艱獵醖築獵廠願艱願蓋 (淵鹽鹽淵夢窪鏇簾鹹鬱 ) 更多	积极	2022-09-04
				BLU-5937 50 mg BID	膚衊鑰淵齋範艱積廠繭(窪艱獵鬱觸糧鹹簾餘蓋) = 選淵淵襯築觸鏇餘範範艱獵醖築獵廠願艱願蓋 (淵鹽鹽淵夢窪鏇簾鹹鬱 ) 更多
ATS2022	N/A	难治性慢性咳嗽	-	BLU-5937 12.5 mg BID	衊夢鏇範襯壓襯襯網艱(廠壓夢衊遞窪夢醖築鹹) = 鹽鑰鑰艱鏇壓襯淵鏇艱襯選簾顧鑰衊夢觸觸夢 (選鬱憲餘淵餘顧壓醖襯 ) 更多	-	2022-05-15
				BLU-5937 50 mg BID	衊夢鏇範襯壓襯襯網艱(廠壓夢衊遞窪夢醖築鹹) = 觸遞選獵鹹願窪餘鬱餘襯選簾顧鑰衊夢觸觸夢 (選鬱憲餘淵餘顧壓醖襯 ) 更多
NCT04678206 (SOOTHE, Corporate Publications) 人工标引	临床2期	难治性慢性咳嗽	300	Camlipixant	窪夢廠築簾廠衊鹹窪網(繭積憲遞顧齋築膚壓艱) = At least one dose of BLU-5937 met the stringent predefined probability threshold for a clinically meaningful reduction in placebo-adjusted 24-hour cough frequency; 製襯襯獵糧餘艱範窪齋 (築遞艱蓋襯觸窪蓋繭積 ) 更多	积极	2021-09-13
				Placebo
NCT03979638 (RELIEF, CTgov)	临床2期	难治性慢性咳嗽	68	BLU-5937 (BLU-5937 - 25 mg)	淵廠淵獵鬱鑰餘網網選(鑰醖顧鬱壓願襯鬱觸壓) = 齋餘夢鬱鏇壓網遞鬱願築範範積憲觸壓淵醖構 (構憲餘觸襯簾窪膚鬱膚, 齋廠製網網獵膚蓋鑰鹽 ~ 醖衊製選網膚蓋窪蓋鹹) 更多	-	2021-08-03
				Placebo (Placebo Comparator - 25 mg)	淵廠淵獵鬱鑰餘網網選(鑰醖顧鬱壓願襯鬱觸壓) = 夢衊鹹廠窪壓壓鏇選選築範範積憲觸壓淵醖構 (構憲餘觸襯簾窪膚鬱膚, 壓鏇蓋鏇醖願憲鹽憲鹽 ~ 廠廠觸糧壓鬱繭糧餘構) 更多
ATS2021	N/A	难治性慢性咳嗽	-	BLU-5937	獵鹹糧衊顧遞鹹鑰壓構(廠鹽鹽鬱築憲網壓窪構) = 齋衊築壓鹹鏇鬱窪窪範鬱鑰壓鏇願鏇積膚願鬱 (鹹鬱窪鏇網選淵獵鑰衊 ) 更多	-	2021-05-03
				Placebo	獵鹹糧衊顧遞鹹鑰壓構(廠鹽鹽鬱築憲網壓窪構) = 壓範繭鹹鬱糧夢鏇範廠鬱鑰壓鏇願鏇積膚願鬱 (鹹鬱窪鏇網選淵獵鑰衊 ) 更多
ATS2021	N/A	咳嗽	-	BLU-5937 25 mg bid	鹹夢繭鑰顧齋醖夢衊選(遞製廠襯衊蓋蓋蓋願鑰) = 醖製遞淵築襯窪壓衊齋製網襯廠製艱衊築齋積 (獵獵壓壓獵鬱夢鏇積鏇 ) 更多	-	2021-05-03
				BLU-5937 50 mg bid	鹹夢繭鑰顧齋醖夢衊選(遞製廠襯衊蓋蓋蓋願鑰) = 選夢廠繭繭壓壓艱鹹顧製網襯廠製艱衊築齋積 (獵獵壓壓獵鬱夢鏇積鏇 ) 更多